Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer

PURPOSE: The GEST study showed non-inferiority of S-1 but not superiority of gemcitabine plus S-1 (GS) to gemcitabine alone for overall survival with the data by the cut-off date of 31st July in 2010 for chemo-naïve patients with advanced pancreatic cancer. We considered it important to determine wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Okusaka, Takuji, Miyakawa, H., Fujii, H., Nakamori, S., Satoh, T., Hamamoto, Y., Ito, T., Maguchi, H., Matsumoto, S., Ueno, H., Ioka, T., Boku, N., Egawa, S., Hatori, T., Furuse, J., Mizumoto, K., Ohkawa, S., Yamaguchi, T., Yamao, K., Funakoshi, A., Chen, J. S., Cheng, A. L., Sato, A., Ohashi, Y., Tanaka, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Article – Clinical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427167/
https://www.ncbi.nlm.nih.gov/pubmed/28210843
http://dx.doi.org/10.1007/s00432-017-2349-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427167/
https://www.ncbi.nlm.nih.gov/pubmed/28210843
http://dx.doi.org/10.1007/s00432-017-2349-y

Ejemplares similares